Upfront treatment with medications that target the underlying pathophysiology of prediabetes may slow patients’ progression to type 2 diabetes, report researchers.
The results of a network meta-analysis offer strong support for use of sodium-glucose cotransporter 2 inhibitors to prevent heart failure (HF) in patients with type 2 diabetes.
Findings from a dose-ranging phase II trial published in The Lancet suggest that semaglutide, in combination with lifestyle intervention, may aid weight loss in people with obesity who do not have diabetes.
Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of sodium-glucose co-transporter-2 inhibitors in patients affected by acute coronary syndromes.
Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of glucagon-like peptide-1 receptor agonists in patients affected by acute myocardial infarction.
What do the results of CVOTs mean for practicing clinicians? Medicine Matters contributor, Carol Wysham reviews the latest evidence and guidelines for reducing CV risk in patients with type 2 diabetes.
medwireNews outlines which medications have so far been tested as adjunct treatments for type 1 diabetes and summarizes the key trial data showing their benefits or otherwise.
With four GLP-1 receptor agonists now having published cardiovascular outcome data, medwireNews takes a look at how the experts are interpreting the conflicting findings, and what they mean for prescribing decisions.